Propel Bio Management’s Orchestra BioMed OBIO Stock Holding History

Propel Bio Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.87M	Hold	896,701	–	–	2.02%	16
2026 Q1	$3.83M	Buy	+896,701	New	+$3.82M	2.41%	15

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Propel Bio Management's OBIO Position: Q2 2026 in Review

Propel Bio Management held its Orchestra BioMed (OBIO) position steady in Q2 2026 at 896,701 shares worth $3.87M. The position accounts for 2.02% of the portfolio, ranked #16.

Propel Bio Management first reported a position in OBIO in Q1 2026 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

Propel Bio Management held 896,701 shares of Orchestra BioMed worth $3.87M as of Q2 2026.
Propel Bio Management left its Orchestra BioMed share count unchanged in Q2 2026.
Orchestra BioMed made up 2.02% of Propel Bio Management's portfolio in Q2 2026, its #16 holding.
Propel Bio Management first reported a position in Orchestra BioMed in Q1 2026 and has held it in 2 quarters since.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.